Novelion Therapeutics Appoints Mark Corrigan, M.D. to Board of Directors
March 31 2017 - 8:00AM
Novelion Therapeutics Inc. (NASDAQ:NVLN)
(TSX:NVLN), a biopharmaceutical company dedicated to developing new
standards of care for individuals living with rare diseases, today
announced the appointment of Mark Corrigan, M.D. to its board of
directors, effective immediately. Dr. Corrigan will serve as a
member of the compliance committee.
Jason Aryeh, chairman of the board of directors,
said, “As a highly successful industry executive and board member,
we believe Dr. Corrigan will be a strong contributor to the
strategic direction of Novelion, particularly as we seek to
maximize the value of metreleptin by expanding the pipeline of
indications in development. In addition, we believe Dr. Corrigan's
complementary scientific expertise and strong strategic track
record will augment the new Board's focus on maximizing shareholder
value with proper compliance and strong corporate governance.”
Dr. Corrigan was previously president and
chief executive officer of Zalicus Inc. Prior to that, he was
executive vice president, research & development of Sepracor
Inc. (now Sunovion Pharmaceuticals). Prior to joining Sepracor, Dr.
Corrigan spent 10 years with Pharmacia & Upjohn, Inc., most
recently as group vice president of global clinical research and
experimental medicine. Dr. Corrigan currently serves on the board
of directors of Cardiome Pharma Corp. (NASDAQ:CRME) and on the
supervisory board of Nabriva Therapeutics AG (NASDAQ:NBRV). He
previously served as a director of CoLucid Pharmaceuticals, Inc.,
Avanir Pharmaceuticals, Inc., EPIRUS Biopharmaceuticals, Inc. and
Cubist Pharmaceuticals, Inc. He was chairman of the board of EPIRUS
and served on the audit committee and nominating and governance
committee and chaired the scientific affairs committee of Cubist’s
board.
Dr. Corrigan spent five years in academic
research at the University of North Carolina Medical School,
focusing on psychoneuroendocrinology. Dr. Corrigan holds a B.A. and
an M.D. from the University of Virginia and received specialty
training in psychiatry at Maine Medical Center and Cornell
University.
The company also announced that effective
immediately, Sandford (“Sandy”) Smith will step down from the
Novelion Board of Directors.
“We thank Sandy for serving as vice chairman,
and for his shared vision towards the creation of Novelion
Therapeutics,” continued Mr. Aryeh.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company dedicated to
developing new standards of care for individuals living with rare
diseases. Novelion has a diversified commercial portfolio through
its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which
includes MYALEPT® and JUXTAPID®, and is also developing zuretinol
acetate for the potential treatment of inherited retinal disease
caused by underlying mutations in RPE65 or LRAT genes. The company
seeks to advance its portfolio of rare disease therapies by
investing in science and clinical development.
Forward Looking
StatementsCertain statements in this press release may
constitute “forward looking information” within the
meaning of applicable Canadian and United States
securities laws. Forward looking statements include statements
regarding our plans to maximize the value of metreleptin by
expanding the pipeline of indications in development. All such
forward looking statements involve assumptions that, although
believed to be reasonable based on information currently available
to management, are subject to risks, uncertainties and other
factors that could cause actual results to differ materially from
the results expressed in the statements. You should not place undue
reliance on any such forward-looking statements.
For additional disclosure regarding these and
other risks we face, see the disclosure contained in the "Risk
Factors" section of Novelion's Annual Report on Form 10-K filed on
March 30, 2017, available on the SEC's website at www.sec.gov.
Except as required by law, we undertake no obligation to update or
revise the information contained in this press release, whether as
a result of new information, future events or circumstances or
otherwise.
Investors and others should note that we
communicate with our investors and the public using our company
website www.novelion.com, including, but not limited to, company
disclosures, investor presentations and FAQs, SEC filings, press
releases, public conference calls transcripts and webcast
transcripts. The information that we post on these websites could
be deemed to be material information. As a result, we encourage
investors, the media and others interested to review the
information that we post there on a regular basis. The contents of
our website shall not be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended.
CONTACT:
Amanda Murphy, Director, Investor & Corporate Communications
Novelion Therapeutics
857-242-5024
amanda.murphy@novelion.com
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Apr 2023 to Apr 2024